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Objectives
No randomized controlled trials have yet reported an individual patient benefit of initiating
combination antiretroviral therapy (cART) at CD4 counts > 350 cells/lL. It is hypothesized that
earlier initiation of cART in asymptomatic and otherwise healthy individuals may lead to poorer
adherence and subsequently higher rates of resistance development.
Methods
In a large cohort of HIV-positive individuals, we investigated the emergence of new resistance
mutations upon virological treatment failure according to the CD4 count at the initiation of cART.
Results
Of 7918 included individuals, 6514 (82.3%), 996 (12.6%) and 408 (5.2%) started cART with a CD4
count ≤ 350, 351–499 and ≥ 500 cells/lL, respectively. Virological rebound occurred while on cART
in 488 (7.5%), 46 (4.6%) and 30 (7.4%) with a baseline CD4 count ≤ 350, 351–499 and ≥ 500 cells/lL,
respectively. Only four (13.0%) individuals with a baseline CD4 count > 350 cells/lL in receipt of a
resistance test at viral load rebound were found to have developed new resistance mutations. This
compared to 107 (41.2%) of those with virological failure who had initiated cART with a CD4 count
< 350 cells/lL.
Conclusions
We found no evidence of increased rates of resistance development when cART was initiated at
CD4 counts above 350 cells/lL.
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Introduction
Although morbidity and mortality benefits of starting
combination antiretroviral therapy (cART) at CD4 counts
> 350 cells/lL have been reported in cohort studies
[1,2], there is little randomized evidence on the individ-
ual risk–benefit ratio of initiating combination antiretro-
viral therapy (cART) at higher CD4 counts [3]. The
randomized controlled Strategic Timing of AntiRetroviral
Treatment (START) trial has recently investigated the
optimal timing of cART initiation in order to improve
morbidity and mortality outcomes in HIV-positive indi-
viduals [4]. Nevertheless, there have already been
changes to national and international HIV treatment
guidelines [5,6], largely driven by the impact of cART
on viral transmission [7] and a pragmatic approach to
cART roll out programmes.
As adherence to cART has been associated with
perceived “need” for treatment [8], there is concern that a
recommendation to start cART at higher CD4 counts may
be met with patients’ ambivalence to cART, leading to
suboptimal adherence and antiretroviral resistance. How-
ever, there are no data reported in support of this
hypothesis to date [9,10]. The START trial will investigate
Correspondence: Sophie Jose, Research Department of Infection and
Population Health UCL, Royal Free Campus, London, NW3 2PF, UK. Tel:
02077940500, ext. 36763; e-mail: sophie.jose@ucl.ac.uk
†The UK CHIC and UK HDRD Steering Committees members are listed in
Appendix 1.
This is an open access article under the terms of the Creative Commons
Attribution License, which permits use, distribution and reproduction in
any medium, provided the original work is properly cited.
368
DOI: 10.1111/hiv.12302
© 2015 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association. HIV Medicine (2016), 17, 368--372
SHORT COMMUNICATION
antiretroviral resistance development as a secondary
endpoint, and will report these findings after 2016.
Previously, we reported on laboratory-defined adverse
events (LDAEs) according to the CD4 count at initiation
of cART [11]. We now describe rates of new antiretroviral
resistance mutations in those experiencing virological
failure, according to the CD4 count at treatment initia-
tion.
Methods
The UK Collaborative HIV Cohort (CHIC) Study collates
routinely collected clinical data on HIV-positive individu-
als accessing care across several centres in the UK. The
study was approved by a multicentre research ethics
committee and by local ethics committees and does not
require informed consent. Similarly, the UK HIV Drug
Resistance Database (HDRD) collates results of routine
resistance testing of HIV-positive individuals accessing
care. A combined UK CHIC – UK HDRD dataset was used
for analysis. Individuals were included who initiated
cART (≥ 3 antiretroviral drugs) between 2000 and 2011
with a baseline CD4 count and resistance test result avail-
able, and who achieved an undetectable viral load on
cART. Pregnant women were excluded.
Virological rebound was defined at the first occurrence
of two consecutive viral loads > 400 HIV-1 RNA copies/
mL following an undetectable viral load. Virological
rebound occurring while on cART was classed as treat-
ment failure and evaluated for resistance development.
Virological rebound that occurred immediately following
a treatment discontinuation was not evaluated for
resistance development. The earliest resistance test result
available up to 1 month before or 6 months after the
date of virological failure was used. We defined new
resistance as the presence of any new major resistance
mutation [12] not present in the baseline genotype, strati-
fying results according to the CD4 count at cART initia-
tion (≤ 350, 351–499 and ≥ 500 cells/lL).
Results
In total, 9288 people had initiated cART since 2000 and
had a baseline CD4 count and resistance test result avail-
able. Of these, 8445 (91%) achieved an undetectable viral
load. A further 527 were excluded due to pregnancy. Of
7918 included, 6514 (82.3%), 996 (12.6%) and 408 (5.2%)
started cART with a CD4 count ≤ 350, 351–99 and ≥ 500
cells/lL, respectively.
Those with a baseline CD4 count 351–499 or ≥ 500
cells/lL were more likely to be men who have sex with
men (MSM), of white ethnicity, co-infected with HCV and
having started cART in a later calendar year than those
with a baseline CD4 count ≤ 350 cells/lL (P < 0.0001).
Those with a CD4 count ≥ 500 cells/lL were more likely
to start a ritonavir-boosted protease inhibitor (PI/r)-based
regimen (43.9 vs. 29.3% 351–499 cells/lL and 25.8%
< 350 cells/lL) and less likely to start a nonnucleoside
reverse transcriptase inhibitor (NNRTI)-based regimen
(52.0 vs. 64.7% and 69.5%, respectively). At baseline, 255
(4.0%), 26 (2.7%) and 23 (5.9%) of those with CD4 count
≤ 350, 351–499 and ≥ 500 cells/lL were not fully suscep-
tible to ≥ 1 drug in their cART regimen (P = 0.02).
Virological rebound occurred in 806 (10.2%) individu-
als, of whom 564 were receiving cART at the time of
rebound: 488 (7.5%), 46 (4.6%) and 30 (7.4%) with a
baseline CD4 count ≤ 350, 351–499 and ≥ 500 cells/lL,
respectively. A higher proportion of individuals with a
baseline CD4 count ≤ 350 cells/lL received a resistance
test at virological failure (Table 1). By the time of viro-
logical failure, 30.0% had changed their cART regimen
class, and 38.5, 54.4 and 53.3% were on PI/r-based, and
45.3, 34.8 and 40.0% were on a NNRTI-based regimens
(≤ 350, 351–499 and ≥ 500 cells/lL, respectively). The
median (interquartile range) viral load was 3.9 (3.1, 4.8),
4.3 (3.4, 5.0) and 3.6 (3.4, 4.5) log10copies/mL and 18.9,
15.2 and 13.3% had a viral load < 1000 copies/mL
(≤ 350, 351–499 and ≥ 500 cells/lL, respectively). Only
four of 30 with a baseline CD4 count > 350 cells/lL had
evidence of new resistance mutations at viral load
rebound. All mutations conferred resistance to either the
nucleoside reverse transcriptase inhibitor (NRTI) or NNRTI
class of antiretroviral drugs. New PI, NNRTI and NRTI
resistance mutations were found in 3.3, 26.5 and 27.3%
of those with a baseline CD4 count ≤ 350 cells/lL and
18.1% had resistance to more than one class of antiretro-
viral drug.
Discussion
Our results do not demonstrate an increased risk of viro-
logical failure on cART when therapy is initiated at CD4
counts > 350 cells/lL. In fact, there appeared to be a
reduced risk of developing a major resistance mutation
when cART was initiated at CD4 counts > 350 cells/lL.
Greater use of PI/r-based regimens with a higher genetic
barrier to resistance in this group may explain the effect
of seeing fewer resistance mutations emerge when viro-
logical failure occurred [13]. However, our findings are
consistent with other studies [9,10].
Higher rates of virological rebound were observed in
the group that started cART at CD4 counts above 500
cells/lL. The majority of rebounds in this group occurred
following treatment discontinuation, with the proportion
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of patients experiencing rebound while reportedly still
receiving cART being similar across groups. Reasons for
treatment discontinuation in this group are unknown;
however, it is possible that some of these individuals
were enrolled in trials of treatment interruption strategies
that were undertaken during this time period [14]. How-
ever, this trend towards more treatment interruption in
those starting cART with a high CD4 count raises some
concerns. Depending on the specific drugs included in the
regimen as well as the timing of stopping, there is the
potential for viral replication to occur in the presence of
sub-optimal levels of cART following treatment discon-
tinuation, thus leading to selection of drug-resistant
virus, particularly for regimens containing NNRTIs [15].
Of those who experienced virological rebound following
treatment interruption [45 (11%) ≥ 500, 42 (4.2%) 351–
499, 155 (2.4%) ≤ 350 cells/lL), nine (20%), nine (21)%
and 62 (40%) had a resistance test (> 500, 351–499 and
< 350 cells/lL, respectively) with only one (11.1%) per-
son having new resistance mutations detected for CD4
counts 351–499 cells/lL and 15 (24.2%) for CD4 counts
≤ 350 cells/lL.
Fewer resistance tests appeared to be undertaken in
individuals experiencing virological failure who had initi-
ated treatment with CD4 counts > 350 cells/lL, raising
concerns that resistance mutations may be missed in this
group. However, this may be a chance finding and rea-
sons for a lower rate of testing in this group are unclear;
lower viral load at virological failure did not appear to
explain this and no significant predictors of resistance
testing at virological failure were found in any CD4
strata.
Our analyses are limited because reasons for starting
cART at high CD4 counts outside current national guide-
lines are not known. Caucasians and MSM were over-
represented amongst those starting therapy with CD4
counts > 350 cells/lL, indicating that subgroups tradi-
tionally presenting to HIV services earlier in the United
Kingdom tend to initiate treatment earlier [16]. This may
indicate an underlying selection bias amongst those start-
ing therapy early, as native English speakers and UK
nationals with greater access to healthcare and of poten-
tially higher educational status may opt to start therapy
earlier. However, repeating our analysis including only
MSM, we saw similar patterns by CD4 count strata, with
35.1, 12.5 and 11.1% of those with CD4 counts < 350,
351–499 and > 500 cells/lL (respectively) having new
resistance mutations when tested at virological rebound.
Furthermore, in this observational setting, those who
have been motivated to start cART at higher CD4 counts
may be more likely to have better adherence to treatment
and may therefore be less likely to either experience viro-
logical rebound or develop resistance to antiretrovirals.
Despite certain limitations, we have not found evidence
of an increased risk of resistance development at virolog-
ical failure amongst people initiating cART at CD4 counts
> 350 cells/lL.
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Table 1 Virological failure and development of resistance according to CD4 count at combination antiretroviral theraphy (cART) initiation
Baseline CD4 count,
cells/lL N
Virological
rebound defined,
n (%)
Virological
rebound
occurring on
treatment, n (%)
Resistance test,
n (%)
≥ 1 new resistance
mutation, n (%)
PI resistance,
n (%)
NNRTI resistance,
n (%)
NRTI
resistance,
n (%)
≤ 350 6514 643 (9.9) 488 (7.5) 260 (53.3) 107 (41.2) 8 (3.1) 69 (26.5) 71 (27.3)
351–499 996 88 (8.8) 46 (4.6) 20 (43.5) 3 (15.0) 0 (0.0) 3 (15.0) 2 (10.0)
≥ 500 408 75 (18.4) 30 (7.4) 10 (33.3) 1 (10.0) 0 (0.0) 1 (10.0) 1 (10.0)
Total 7918 806 (10.2) 564 (7.1) 290 (51.4) 111 (38.3) 8 (1.4) 73 (25.2) 74 (25.5)
P-value* < 0.0001 0.005 0.056 0.012
PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor, NRTI, nucleoside reverse transcriptase inhibitor.
940 (11.9%) people had at least one major resistance mutation at baseline; of these, 778 (11.9%), 113 (11.4%) and 49 (12.0%) had baseline CD4 count
≤ 350, 351–499 and ≥ 500 cells/lL (P = 0.86).
*All P-values based on a chi squared test.
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